Several brokerages have updated their recommendations and price targets on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) in the last few weeks:

  • 7/18/2017 – Teva Pharmaceutical Industries Limited had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $41.00 price target on the stock.
  • 7/17/2017 – Teva Pharmaceutical Industries Limited had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $37.00 price target on the stock, down previously from $38.00.
  • 7/17/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Teva continues to progress with its branded and generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing significantly to the growth of its generics business. Teva aggressively cuts costs to offset pricing erosion in the U.S. generics business. Estimates have gone up slightly ahead of the company’s Q2 earnings release. Teva has a positive record of earnings surprises in recent quarters. However, there are significant challenges for Teva in the near term as headwinds remain in the form of generic competition for Copaxone, new competition for branded products, fewer large generic opportunities, U.S. generic pricing pressure, a higher cost base and debt level and the sudden departure of its chief executive office.  Also, Teva’s shares underperformed the generic industry so far this year.”
  • 7/13/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Maxim Group. They now have a $35.00 price target on the stock.
  • 7/12/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $31.74 price target on the stock.
  • 7/11/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/11/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $32.27 price target on the stock.
  • 7/5/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/4/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $32.27 price target on the stock.
  • 6/28/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $32.27 price target on the stock.
  • 6/27/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Wells Fargo & Company.
  • 6/27/2017 – Teva Pharmaceutical Industries Limited was given a new $41.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 6/23/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $33.00 price target on the stock.
  • 6/22/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $31.05 price target on the stock.
  • 6/22/2017 – Teva Pharmaceutical Industries Limited was given a new $31.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 6/16/2017 – Teva Pharmaceutical Industries Limited was given a new $38.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 6/15/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Mizuho from a “neutral” rating to a “buy” rating. They now have a $30.00 price target on the stock, up previously from $25.00.
  • 6/15/2017 – Teva Pharmaceutical Industries Limited is now covered by analysts at Cantor Fitzgerald. They set a “neutral” rating and a $31.00 price target on the stock.
  • 6/13/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/12/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $31.05 price target on the stock.
  • 6/5/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $32.04 price target on the stock.
  • 6/2/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 5/31/2017 – Teva Pharmaceutical Industries Limited had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 5/29/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $32.04 price target on the stock.
  • 5/22/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $31.94 price target on the stock.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up 0.88% during midday trading on Tuesday, hitting $32.11. 3,834,217 shares of the stock were exchanged. Teva Pharmaceutical Industries Limited has a 12-month low of $27.59 and a 12-month high of $55.79. The firm has a market cap of $32.62 billion, a P/E ratio of 411.67 and a beta of 0.46. The firm has a 50 day moving average of $30.42 and a 200 day moving average of $32.94.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, May 11th. The company reported $1.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The company had revenue of $5.63 billion during the quarter, compared to the consensus estimate of $5.69 billion. During the same period in the previous year, the firm earned $1.20 earnings per share. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 17.0% on a year-over-year basis. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.76 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, June 22nd. Stockholders of record on Monday, June 5th were paid a $0.34 dividend. The ex-dividend date of this dividend was Thursday, June 1st. This represents a $1.36 annualized dividend and a dividend yield of 4.27%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently 5,802.90%.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.